Results 121 to 130 of about 115,860 (261)

A Novel IDO1/NE Dual Inhibitor, IMM‐H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression

open access: yesAdvanced Science, EarlyView.
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou   +11 more
wiley   +1 more source

An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer. [PDF]

open access: yesOncoimmunology
Lucantonio L   +15 more
europepmc   +1 more source

Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery

open access: yesAdvanced Science, EarlyView.
Systematic engineering of hydrophobic tail architecture in vitamin B5‐derived ionizable lipids establishes a comprehensive structure–activity relationship framework for mRNA delivery. Combined lipidtail and formulation optimization identifies TM1‐OPT3‐C, a lipid nanoparticle platform that improves efficacy–safety balance through efficient mRNA delivery,
Seo‐Hyeon Bae   +27 more
wiley   +1 more source

Targeted β‐Glucan‐Veiled Oral Apremilast Nanotherapy Modulates Key Dysbiosis‐Associated Gut Microbiota and Alleviates Ulcerative Colitis‐Associated Anxiety, Depression, and Neuropsychiatric Behaviors

open access: yesAdvanced Science, EarlyView.
This study introduces β‐glucan‐shielded apremilast laden nanomicelles that withstand gastrointestinal degradation, selectively accumulate in inflamed colon tissue, and modulate the microbiota–gut–brain axis. The formulation restores barrier integrity, reduces systemic and neuroinflammation, and improves anxiety‐ and depression‐like behaviors in colitis
Chandrashekhar Jori   +10 more
wiley   +1 more source

CD8+ T Lymphocytes in Pituitary Neuroendocrine Tumors: Friend or Foe? [PDF]

open access: yesCells
Nastase VN   +9 more
europepmc   +1 more source

LRG1 Drives Pathological Angiogenesis by Disrupting Neutrophil Mitochondrial Homeostasis in Bladder Cancer

open access: yesAdvanced Science, EarlyView.
In bladder cancer, LRG1 binds to ANXA2 to trigger mitochondrial ROS‐dependent NETosis. This pathogenic cascade actively uncouples endothelial‐mural cell interactions, driving profound vascular destabilization. Consequently, targeting the LRG1‐ANXA2 axis attenuates the neutrophil burden and induces structural vascular normalization, offering a powerful ...
Dongshan Chen   +8 more
wiley   +1 more source

Activation of tumor-specific CD8+ T cells prior to radiopharmaceutical therapy improves antitumor response. [PDF]

open access: yesJ Immunother Cancer
Shim D   +8 more
europepmc   +1 more source

A Programmable Calcification Nanoplatform for Loco‐Regional Calcification‐Immune Hepatocellular Carcinoma Therapy

open access: yesAdvanced Science, EarlyView.
An in situ‐grown BP‐CaO2 nanoplatform supplies coordinated Ca2+, endogenous phosphate, and oxidative stress to convert tumor calcification from a passive endpoint into an active immune‐remodeling process. Widespread hydroxyapatite deposition is visualized by CT, while multi‐omics reveals MCOLN2 as a calcium‐responsive mediator linking biomineralization
Long Liu   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy